Ergoteles’s Cardlytics CDLX Stock Holding History

Ergoteles’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,812	Closed	-$95.5K	–	1090
2023 Q1	$95.5K	Buy	+2,812	New	+$147K	﹤0.01%	1107
2022 Q4	–	Sell	-4,190	Closed	-$394K	–	1492
2022 Q3	$394K	Buy	+4,190	New	+$596K	0.01%	857
2022 Q2	–	Sell	-1,114	Closed	-$613K	–	1669
2022 Q1	$613K	Sell	1,114 -1,163	-51%	-$703K	0.02%	599
2021 Q4	$1.5M	Buy	+2,277	New	+$1.74M	0.06%	323

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's CDLX Position: Q2 2023 in Review

Ergoteles sold out of Cardlytics (CDLX) in Q2 2023, closing a stake of 2,812 shares — an estimated $95.5K sold.

Ergoteles first reported a position in CDLX in Q4 2021 and held it in 4 quarters. The position peaked at $1.5M in Q4 2021. 110 funds tracked by Wall St. Rank hold CDLX as of Q2 2023.

Ergoteles reported no remaining Cardlytics position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 2,812 Cardlytics shares in Q2 2023, an estimated $95.5K.
Ergoteles first reported a position in Cardlytics in Q4 2021 and held it in 4 quarters.
Ergoteles's Cardlytics position peaked at $1.5M in Q4 2021.
110 funds tracked by Wall St. Rank held Cardlytics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.